Home - Clinical Trials Arena
From Our Partners. Optimizing Cell & Gene Therapy Processes. Accelerating Clinical Trials. Improving decentralized trials with mobile research nursing. The next chapter of clinical trial services. Trusted clinical trial packaging services. Meet critical milestones. News. Analysis.
Gilead’s lenacapavir: HIV prospects strongest in long-acting …
Aug 25, 2021 · Gilead’s lenacapavir will find its strongest niche as a long-acting HIV combination treatment, experts said. Manasi Vaidya August 25, 2021. Gilead announced a collaboration with Merck in March to study lenacapavir with islatravir, a nucleoside reverse transcriptase translocation inhibitor (NRTTI), which is also a new drug class in HIV.
Biomea’s stock bounces back as FDA lifts clinical hold on diabetes …
Sep 27, 2024 · Biomea Fusion’s stock is on the up after the company plans to resume two clinical trials evaluating its type 1 and 2 diabetes therapy after the US Food and Drug Administration (FDA) lifted a full clinical hold. In June, the US regulatory agency paused the trials of BMF-219 after reports of potential drug-induced hepatotoxicity emerged.
News - Clinical Trials Arena
Adaptive deep brain stimulation trial results poised to “transform” Parkinson’s disease. A new type of self-adjusting neuromodulation is poised to transform the landscape of neurology, as per analyst reaction to results…. Robert Barrie.
Top Ongoing mRNA Herpes Vaccine Trials - Clinical Trials Arena
Feb 2, 2023 · Pfizer and Moderna eye seasonal influenza. The two largest mRNA vaccine trials with readouts in 2023 are for seasonal influenza. First up, Moderna’s 6,102-patient, Phase III trial of mRNA-1010 (NCT05415462) has immunogenicity data expected in Q1 2023. The trial is testing mRNA-1010 against an active comparator vaccine, with primary endpoints ...
Obesity: Six trials to watch over the next 12 months
Jun 30, 2023 · Denmark-based Novo Nordisk’s are reaching the end of the OASIS trials for another oral version of semaglutide (NN-9932) specifically for the use of patients with obesity. OASIS1 has already reached the primary endpoint in a Phase IIIa trial, with results published in May 2023 with reports of 15.1% weight loss, a similar efficacy rating to Wegovy.
Alzheimer's trials: How does donanemab compare to lecanemab?
Jan 13, 2023 · Already, 2023 is shaping up to be an eventful year in Alzheimer’s disease (AD) drug development. After the FDA’s approval of Eisai/Biogen’s Leqembi (lecanemab) on January 6, the AD field is now looking toward the upcoming approval decision for Lilly’s donanemab expected in May. Although both donanemab and lecanemab have similar therapeutic targets, the two AD antibodies employed ...
Biosimilars: top 10 pharma companies leading the way
Jan 20, 2022 · Yesterday (19 January), using the same Thematic Research ecosystem, Clinical Trials Arena revealed the top pharma companies best equipped with artificial intelligence. According to our analysis, Novartis, Pfizer, Catalent, Amgen, Biogen, Patheon, Shanghai Henlius Biotech, Viatris, Celltrion, and Samsung Bioepis are the companies best positioned ...
Hepatitis B: Four trials to watch over the next 12 months
Jul 28, 2023 · Hepatitis B immune globulin (Hepatect, Nabi-HB, Zutectra, Neohepatect, Fovepta) contains mainly immunoglobulin G and acts as passive immunising preparation. The two cohorts are HBsAg positive and HBeAg negative, with one group having had no treatment while the other group will have been treated with anti-HBV NUC for at least 12 months before ...
ICON closes $12bn acquisition of PRA Health Sciences
Jul 2, 2021 · The merged company will operate as ICON from 150 locations across 47 countries. Divya Tirumalaraju July 2, 2021. ICON has concluded the previously announced acquisition of contract research company PRA Health Sciences for a total consideration of approximately $12bn. Free Whitepaper.